Clinical features and effectiveness of treatment of patients with pulmonary tuberculosis who have had COVID-19

DOI: https://doi.org/10.29296/25877305-2023-12-09
Issue: 
12
Year: 
2023

A. Zakharov(1), MD; N. Karpina(1), MD; N. Chernykh(1), Candidate of Medical Sciences; R. Amansakhedov(1), MD; Professor I. Stepanyan(1), MD; Professor V. Romanov(1), MD; Professor A. Ergeshov(1, 2), Corresponding Member of the Russian Academy of Sciences, MD
1-Central Research Institute of Tuberculosis, Moscow
2-Russian University of Medicine, Ministry of Health of Russia, Moscow

In May 2023, WHO officially declared the end of the COVID-19 pandemic. Assessing the consequences of the pandemic remains scientifically and practically relevant. Patients who have recovered from COVID-19 are at risk of developing or relapsing tuberculosis (TB). A comparative retrospective-prospective study was conducted on 88 patients with pulmonary TB, including 45 patients after COVID-19. In 68.9% of those examined, COVID-19 was mild. Tuberculomas and focal pulmonary TB predominated in patients. Tuberculomas and focal pulmonary TB predominated in patients. The most common patterns on CT scans were ground-glass and severe changes. Among laboratory parameters, increases in fibrinogen, D-dimer, and C-reactive protein were more often observed. COVID-19, which was mostly mild, did not have a significant impact on the effectiveness of treatment for TB patients. At the same time, such patients had a more frequent development of adverse reactions during anti-tuberculosis chemotherapy and a complicated course of pulmonary TB.
Keywords: 
pulmonary tuberculosis
new coronavirus infection SARS-CoV-2
COVID-19
post-Covid syndrome.

References: 
  1. World Health Organization. Coronavirus disease (COVID-2019) situation reports. URL: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200708-covid-19-sitrep-170.pdf?sfvrsn=bca86036_2
  2. Ларина В.Н., Рыжих А.А., Бикбаева Л.И. Постковидный период: современный взгляд и клинические особенности. Архивъ внутренней медицины. 2021; 11(3): 186–95 [Larina V.N., Ryzhikh A.A., Bikbaeva L.I. Post-COVID 19 Period: Modern State and Clinical Features. The Russian Archives of Internal Medicine. 2021; 11 (3): 186–95 (in Russ.)]. DOI: 10.20514/2226-6704-2021-11-3-186-195
  3. Malkova A.M., Kudryavtsev I.V., Starshinova A.A. et al. Post COVID-19 syndrome in patients with asymptomatic/mild form. Pathogens. 2021; 10 (11): 1408. DOI: 10.3390/pathogens10111408
  4. Екатеринчева О.Л., Малкова А.М., Карев В.Е. и др. Особенности диагностики туберкулеза на фоне COVID-19. Журнал инфектологии. 2021; 13 (1): 117–23 [Ekaterincheva O.L., Malkova A.M., Karev V.E. et al. Features of tuberculosis diagnosis in the COVID-19. Journal Infectology. 2021; 13 (1): 117–23 (in Russ.)]. DOI: 10.22625/2072-6732-2021-13-1-117-123
  5. Биличенко Т.Н. Постковидный синдром: факторы риска, патогенез, диагностика и лечение пациентов с поражением органов дыхания после COVID-19 (обзор исследований). РМЖ. Медицинское обозрение. 2022; 6 (7): 367–75 [Bilichenko T.N. Postcovid syndrome: risk factors, pathogenesis, diagnosis and treatment of patients with respiratory damage after COVID-19 (overview). Russian Medical Inquiry. 2022; 6 (7): 367–75 (in Russ.)]. DOI: 10.32364/2587-6821-2022-6-7-367-375
  6. Эргешова Л.А., Борисова А.Ю., Карпина Н.Л. Клинические аспекты сочетания COVID-19 и хронических заболеваний органов дыхания – собственный опыт. Вестник ЦНИИТ. 2022; 4: 28–36 [Ergeshova L.A., Borisova A.Yu., Karpina N.L. Clinical aspects of a comorbidity of COVID-19 and chronic pulmonary disease – our experience. CTRI Bulletin. 2022; 4: 28–36 (in Russ.)]. DOI: 10.57014/2587-6678-2022-4-28-36
  7. Бурячковская Л.И., Мелькумянц А.М., Ломакин Н.В. и др. Повреждение сосудистого эндотелия и эритроцитов у больных COVID-19. Consilium Medicum. 2021; 23 (6): 469–76 [Buryachkovskaya L.I., Melkumyants A.M., Lomakin N.V. et al. Injury of vascular endothelium and erythrocytes in COVID-19 patients. Consilium Medicum. 2021; 23 (6): 469–76 (in Russ.)]. DOI: 10.26442/20751753.2021.6.200939
  8. Эргешов А.Э., Овсянкина Е.С., Губкина М.Ф., и др. Особенности диагностики и течения новой коронавирусной инфекции у детей и подростков с туберкулезом органов дыхания. Вестник ЦНИИТ. 2020; 4: 43–8 [Ergeshov A.E., Ovsyankina E.S., Gubkina M.F. et al. The peculiarities of diagnosis and course of the novel coronavirus infection in children and adolescents with pulmonary TB. CTRI Bulletin. 2020; 4: 43–9 (in Russ.)]. DOI: 10.7868/S2587667820040056
  9. Красникова Е.В., Лепеха Л.Н., Багиров М.А. и др. Хирургическое лечение больных туберкулезом легких, перенесших COVID-19. Мат-лы конф. Оренбургская фтизиатрия и пульмонология. 2022; 1: 78–92 [Krasnikova E.V., Lepekha L.N., Bagirov M.A. et al. Khirurgicheskoe lechenie bol'nykh tuberkulezom legkikh, perenesshikh COVID-19. Mat-ly konf. Orenburgskaya ftiziatriya i pul'monologiya. 2022; 1: 78–92 (in Russ.)].
  10. Красникова Е.В., Лепеха Л.Н., Багиров М.А. и др. Опыт хирургического лечения больных туберкулезом легких, перенесших COVID-19. Мат-лы конф. Актуальные вопросы военной фтизиатрии. Пушкино, 2022; 13: 63–79 [Krasnikova E.V., Lepekha L.N., Bagirov M.A. et al. Opyt khirurgicheskogo lecheniya bol'nykh tuberkulezom legkikh, perenesshikh COVID-19. Mat-ly konf. Aktual'nye voprosy voennoi ftiziatrii. Pushkino, 2022; 13: 63–79 (in Russ.)].
  11. Мишина А.В., Мишин В.Ю., Эргешов А.Э. и др. Новая коронавирусная инфекция (COVID-19), сочетанная с туберкулезом, у больных на поздних стадиях ВИЧ-инфекции с иммунодефицитом. ВИЧ-инфекция и иммуносупрессии. 2021; 13 (1): 80–7 [Mishina A.V., Mishin V.Yu., Ergeshov A.E. et al. New coronoviral infection (COVID-19) combined with tuberculosis in patients at late stages of HIV infection with immunodeficiency. HIV Infection and Immunosuppressive Disorders. 2021; 13 (1): 80–7 (in Russ.)]. DOI: 10.22328/2077-9828-2021-13-1-80-87
  12. Бородулина Е.А., Васнева Ж.П., Вдоушкина Е.С. и др. Особенности гематологических и гемостазиологических показателей при коронавирусной инфекции COVID-19 и внебольничной пневмонии. Acta Biomedica Scientifica. 2021; 6 (1): 40–7 [Borodulina E.A., Vasneva Zh.P. Vdoushkina E.S. et al. Features of hematological and hemostasiological parameters in coronavirus infection COVID-19 and community-acquired pneumonia. Acta Biomedica Scientifica. 2021; 6 (1): 40–7 (in Russ.)]. DOI: 10.29413/ABS.2021-6.1.6
  13. Global tuberculosis report 2022. Geneva: World Health Organization, 2022.
  14. Kant S., Tyagi R. The impact of COVID-19 on tuberculosis: challenges and opportunities. Ther Adv Infect Dis. 2021; 8: 20499361211016972. DOI: 10.1177/20499361211016973
  15. Wang Y., Xu J., Wang Y. et al. Prevalence of comorbid tuberculosis amongst COVID-19 patients: A rapid review and meta-analysis. Int J Clin Pract. 2021; 75: e14867. DOI: 10.1111/ijcp.14867
  16. Васильева И.А., Тестов В.В., Стерликов С.А. Эпидемическая ситуация по туберкулезу в годы пандемии COVID-19 – 2020–2021 гг. Туберкулез и болезни легких. 2022; 100 (3): 6–12 [Vasilyeva I.A., Testov V.V., Sterlikov S.A. Tuberculosis Situation in the Years of the COVID-19 Pandemic – 2020-2021. Tuberculosis and Lung Diseases. 2022; 100 (3): 6–12 (in Russ.)]. DOI: 10.21292/2075-1230-2022-100-3-6-12
  17. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 16. (18.08.2022) [Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Versiya 16. (18.08.2022) (in Russ.)]. URL: https://www.cr.minzdrav.gov.ru
  18. Туберкулез у взрослых. Федеральные клинические рекомендации 2022 г. [Tuberkulez u vzroslykh. Federal'nye klinicheskie rekomendatsii 2022 g. (in Russ.)]. URL: https://www.cr.minzdrav.gov.ru
  19. Ставицкая Н.В., Фелькер И.Г., Жукова Е.М. и др. Многофакторный анализ результатов применения бедаквилина в терапии МЛУ/ШЛУ-туберкулеза легких. Туберкулез и болезни легких. 2020; 98 (7): 56–62 [Stavitskaya N.V., Felker I.G., Zhukova E.M. et al. The multivariate analysis of results of bedaquiline use in the therapy of MDR/XDR pulmonary tuberculosis. Tuberculosis and Lung Diseases. 2020; 98 (7): 56–62 (in Russ.)]. DOI: 10.21292/2075-1230-2020-98-7-56-62
  20. Жукова Е.М., Вохминова Л.Г., Кудлай Д.А. Влияние современной химиотерапии туберкулеза с МЛУ/ШЛУ на изменение у больных интервала QT на ЭКГ. Туберкулез и болезни легких. 2019; 97 (11): 19–22 [Zhukova E.M., Vokhminova L.G., Kudlay D.A. The effect of the current chemotherapy of MDR/XDR tuberculosis on QT interval changes in ECG. Tuberculosis and Lung Diseases. 2019; 97 (11): 19–22 (in Russ.)]. DOI: 10.21292/2075-1 230-2019-97-11-19-22
  21. Lewandowski K., Rosołowski M., Kaniewska M. et al. Clostridioides difficile infection in coronavirus disease 2019 (COVID‑19): an underestimated problem? Pol Arch Intern Med. 2021; 131: 121–7. DOI: 10.20 452/pamw.15715
  22. Spigaglia Р., Clostridioides difficile infection (CDI) during the COVID-19 pandemic. Anaerobe. 2022; 74: 102518. DOI: 10.1016/j.anaerobe.2022.102518
  23. Абдуллаев Р.Ю., Комиссарова О.Г. Невирусологические лабораторные маркеры COVID-19. Вестник ЦНИИТ. 2020; 3: 12–6 [Abdullaev R.Yu., Komissarova O.G. Non-virological laboratory markers of COVID-19. CTRI Bulletin. 2020; 3: 12–6 (in Russ.)]. DOI: 10.7868/S2587667820030024
  24. Смирнова Т.Г., Андреевская С.Н., Ларионова Е.Е. и др. Опыт работы отдела микробиологии ФГБНУ «ЦНИИТ» в условиях пандемии COVID-19. Вестник ЦНИИТ. 2022; 2: 75–80 [Smirnova T.G., Andreevskaya S.N., Larionova E.E. et al. Experience of the microbiology department of the Central TB Research Institute in the context of COVID-19 pandemic. CTRI Bulletin. 2022; 2: 75–80 (in Russ.)]. DOI: 10.7868/S2587667822020091
  25. Тиллоева З.Х. Динамика лекарственной устойчивости возбудителей туберкулеза во время пандемии новой коронавирусной инфекции в г. Душанбе: необходимость принятия срочных мер. Вестник Авиценны. 2022; 24 (3): 353–68 [Tilloeva Z.Kh. Dynamics of drug resistance in M. tuberculosis during the new coronavirus infection pandemic in Dushanbe: The need for urgent measures. Avicenna Bulletin. 2022; 24 (3): 353–68 (in Russ.)]. DOI: 10.25005/2074-0581-2022-24-3-353-368